Team leader

  • All
  • JefeGrupo
  • NEUR02
  • Default
  • Title
  • Date
  • Random
    • JefeGrupo
    • NEUR02

    Ángel Luis Montejo González

    Complejo Asistencial Universitario de Salamanca

    Research Gate

Research team:
  • Carolina Lorenzo Romo
  • Santiago Sánchez Iglesias
 Research associates:
  • Pablo Alonso Hernández
  • Miriam Bersabé Pérez
  • Bárbara Buch Vicente
  • Raquel Cabezas Mesonero
  • Nerea Casado Espada
  • Marina Covacho González
  • Ruben de Alarcón Gómez
  • Francisco del Castillo de la Torre
  • Luz Celia Fenández Martín
  • Clara Isabel Fombellida Velasco
  • Mª Teresa Gallego de Dios
  • Alba González Mota
  • Pilar Gómez Hernández
  • David González Parra
  • Felipe Hernández Zaballos
  • Tomás Martín Pinto
  • Ángel María Martín Sánchez
  • Juan Matias Fernández
  • Josefa Matías Polo
  • Claudia Matos Spöhring
  • Ana Isabel Mitadiel Velasco
  • María Belén Peláez Pezzi
  • Javier Pérez Rodríguez
  • Jose Luis Villegas Martínez
Technical staff:
  • Jose María Acosta Rodríguez
Technical associates:
  • --

Research focus:

  • The study of human sexuality and how it is modified in patients with mental disorders.
  • The study of sexual dysfunctions related to the chronic use of antidepressants, antipsychotic and mood stabilizers. The study of sexual dysfunctions related to other drugs for chronic disorders: hypertension and diabetes.
  • The creation and validation of tools to study these dysfunctions, including their adaptation to other languages. PRSexDQ-SALSEX questionnaire, tool questionnaire. The creation of international collaboration groups studying sexuality and mental health.
  • The study of secondary hyperprolactinemia induced by antipsychotics and its long-term effect on the patients' physical health. Association with amenorrhea, galactorrhea, gynecomasty, osteoporosis, cancer risk, cardiovascular risk, changes in immunity.
  • Clinical trials with new molecules in phase, I, II and III, compared with placebo or standard comparator.
  • Clinical trials with new molecules used as add-on treatment linked to existing treatments.
  • Clinical trails for the evaluation of psychoactive drugs in patients and healthy volunteers. Phase I.


Click to access


Click to access


We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site